Our hope is that our findings will motivate studies of retinal and LGN function in relation to V1 activation and psychophysical task performance (which have not been conducted), across developmental stages of schizophrenia, in both medicated and unmedicated patients, so as to clarify the relative contributions of psychosis, chronicity, and medication effects. The gene discussed is GPSM2; the disease is psychotic disorder.